With your own knowledge and the help of the following document:

Document 1 (Title: Clinical Applications and Pharmacological Properties of Benzodiazepines): Benzodiazepines represent a major psychopharmacological class with diverse clinical applications based on their distinctive pharmacological properties and structural variations. Comprehensive understanding requires accurate characterization of individual agents within this chemically related but functionally diverse medication group. Zopiclone, despite similar clinical effects, represents a structurally distinct cyclopyrrolone lacking the characteristic benzodiazepine diazepine ring structure, demonstrating that similar GABA-ergic effects can arise from chemically unrelated compounds. Metabolic pathways significantly influence clinical applications, with oxazepam's pharmacokinetic profile demonstrating distinctive features as a secondary metabolite produced through hepatic biotransformation of longer-acting benzodiazepines including diazepam. This metabolic relationship creates important considerations in hepatic impairment where parent compound clearance may be reduced while active metabolite formation continues. Individual benzodiazepines demonstrate significant potency variations, with flunitrazepam exhibiting high sedative-hypnotic potency but not necessarily enhanced anxiolytic effects compared to less potent compounds at equipotent doses, contrary to common assumptions regarding potency-effect relationships. Adverse effect profiles distinguish benzodiazepines from other psychotropic classes, with central effects predominantly including sedation, cognitive impairment, psychomotor slowing, and potential paradoxical reactions rather than the extrapyramidal symptoms characteristic of dopamine antagonist medications. Clinical versatility represents a notable characteristic, with certain specific benzodiazepines including midazolam and diazepam finding important applications in anesthesiology practice for conscious sedation, preanesthetic medication, and procedural amnesia due to their rapid onset, short duration, and anticonvulsant properties. These distinctive pharmacological features collectively inform appropriate agent selection, dosing strategies, monitoring requirements, and precautionary measures across diverse clinical scenarios.
Document 2 (Title: Amitriptyline): Continuing Education Activity Amitriptyline is in the tricyclic antidepressant (TCA) drug classification and acts by blocking the reuptake of both serotonin and norepinephrine neurotransmitters. Amitriptyline is an FDA-approved medication to treat depression in adults. The non-FDA approved indications are anxiety, post-traumatic stress disorder, insomnia, chronic pain (diabetic neuropathy, fibromyalgia), irritable bowel syndrome, interstitial cystitis (bladder pain syndrome), migraine prophylaxis, postherpetic neuralgia, and sialorrhea. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of amitryptiline in the clinical setting related to the essential points needed by members of an interprofessional team managing the care of patients with indications that can benefit from amitriptyline therapy. Amitriptyline is in the tricyclic antidepressant (TCA) drug classification and acts by blocking the reuptake of both serotonin and norepinephrine neurotransmitters. The three-ring central structure and a side chain are the basic structure of tricyclic antidepressants. Amitriptyline is a tertiary amine with strong binding affinities for alpha-adrenergic, histamine (H1), and muscarinic (M1) receptors.[6] Amitriptyline increases noradrenergic or serotonergic neurotransmission by blocking the norepinephrine or serotonin transporter (NET or SERT) at presynaptic terminals. Chronic treatment with amitriptyline desensitizes presynaptic autoreceptors and heteroreceptors, producing long-lasting changes in monoaminergic neurotransmission.[7] Amitryptiline is more sedating and has increased anticholinergic properties than other TCAs. As with other antidepressants, the onset of therapeutic action typically begins at approximately 2 to 4 weeks. Amitriptyline toxicity can be serious and even fatal. In treating the toxicity, the top priority is stabilizing the patient, which may require admission to the ICU for monitoring. The most important steps include - protecting the airways, breathing, and stabilizing circulation. Some patients may need tracheal intubation; if required, administer supplemental oxygen. All patients suspected of tricyclic antidepressant overdose should receive gastrointestinal decontamination. This should include large-volume gastric lavage followed by activated charcoal.[41] Seizures secondary to overdose are treatable with diazepam or lorazepam. If the patient is hypotensive, an IV bolus of isotonic crystalloid is a therapeutic option. Vasopressors are the next choice if the patient remains hypotensive despite fluid resuscitation. If QRS exceeds 100 msec, intravenous sodium bicarbonate is the appropriate intervention. Sodium bicarbonate is cardioprotective (it increases extracellular sodium concentration) and diminishes the effect of amitriptyline on the cardiac membrane, resulting in less sodium channel blockage. Alkalization favors the neutral form of amitriptyline and decreases the amount of active cyclic antidepressants.
Document 3 (Title: Urinary Obstruction and Stasis   Kidney): The pressure within the renal pelvis is normally close to zero. When this pressure increases because of obstruction or reflux, the pelvis and calyces dilate. The degree of hydronephrosis that develops depends on the duration, degree, and site of the obstruction (Figure 12–4). The higher the obstruction, the greater the effect on the kidney. If the renal pelvis is entirely intrarenal and the obstruction is at the ureteropelvic junction, all the pressure will be exerted on the parenchyma (Klein et al., 2010). If the renal pelvis is extrarenal, only part of the pressure produced by a ureteropelvic stenosis is exerted on the parenchyma; this is because the extrarenal pelvis is embedded in fat and dilates more readily, thus "decompressing" the hydronephrotic left renal pelvis. Low density mass (P) in the left renal sinus had an attenuation value similar to that of water, suggesting the correct diagnosis. Unless intravenous contrast material is used, differentiation from a peripelvic cyst may be difficult. In the earlier stages, the renal pelvic musculature undergoes compensatory hypertrophy in its effort to force urine past the obstruction. Later, however, the muscle becomes stretched and atonic and decompensated. The progression of hydronephrotic atrophy is as follows (Chevalier, 2010; Rodriguez, 2004): 1. The earliest changes in the development of hydronephrosis are seen in the calyces. The end of a normal calyx is concave because of the papilla that projects into it; with increased intrapelvic pressure, the fornices become blunt and rounded. With persistence of increased intrapelvic pressure, the papilla becomes flattened, then convex (clubbed) as a result of compression enhanced by ischemic atrophy (Figure 12–5). The parenchyma between the calyces is affected to a lesser extent. The changes in the renal parenchyma are due to (a) compression atrophy from increased intrapelvic pressure (more accentuated with intrarenal pelves) and (b) ischemic atrophy from hemodynamic changes, mainly manifested in arcuate vessels that run at the base of the pyramids parallel to the kidney outline and are more vulnerable to compression between the renal capsule and the centrally increasing intrapelvic pressure. 2. This spotty atrophy is caused by the nature of the blood supply of the kidney. The arterioles are end arteries; therefore, ischemia is most marked in the areas farthest from the interlobular arteries. As the back pressure increases, hydronephrosis progresses, with the cells nearest the main arteries exhibiting the greatest resistance. 3. This increased pressure is transmitted up the tubules. The tubules become dilated, and their cells atrophy from ischemia. It should be pointed out that a few instances of dilated renal pelves and calyces are not due to the presence of obstruction. Rarely, the renal cavities are congenitally capacious and thus simulate hydronephrosis. More commonly, hydronephrosis may occur in childhood owing to the back pressure associated with vesicoureteral reflux. If the valvular incompetence resolves (and this is common), some degree of the hydronephrotic changes may persist. These persisting changes may cause the physician to suspect the presence of obstruction, which may lead to unnecessary surgery. A radioisotope renogram to assess ureteral drainage function can be performed to determine whether organic obstruction is present. 4. Only in unilateral hydronephrosis are the advanced stages of hydronephrotic atrophy seen. Eventually, the kidney is completely destroyed and appears as a thin walled sac filled with clear fluid (water and electrolytes) or pus (Figure 12–6).

Answer the following list question.
Question: Select the correct statement(s):
Options:
1. Zopiclone is an anxiolytic benzodiazepine
2. Oxazepam is a secondary metabolite of diazepam
3. Flunitrazepam is a very potent anxiolytic
4. Benzodiazepines cause extrapyramidal side effects
5. Some benzodiazepines can be used in anesthesiology

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ← if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.